Literature DB >> 7675991

Re-engineering drug development: integrating pharmacoeconomic research into the drug development process.

J L Data1, R J Willke, J R Barnes, P J DiRoma.   

Abstract

Pharmacoeconomic research will be an increasingly important aspect of drug development as providers, third-party payers, and worldwide government health agencies use cost-effectiveness and quality-of-life data to assist in making decisions on optimal pharmaceutical treatment protocols, formulary listings, and reimbursement. It is in the best interest of pharmaceutical companies to have an established, well-integrated pharmacoeconomic research program that can respond to the dynamic health-care environment and proactively plan a program to optimize patient care. The new paradigm for pharmacoeconomic research will require establishment and successful management of many internal and external customer relationships. This article discusses one company's organization of these relationships and how they are integrated into the drug development process during each stage of the product life cycle.

Entities:  

Mesh:

Year:  1995        PMID: 7675991

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  3 in total

Review 1.  Economic evaluations during early (phase II) drug development: a role for clinical trial simulations?

Authors:  D A Hughes; T Walley
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  A survey of population-based drug databases in Canada.

Authors:  E Miller; B Blatman; T R Einarson
Journal:  CMAJ       Date:  1996-06-15       Impact factor: 8.262

Review 3.  Measuring quality of life in patients with schizophrenia.

Authors:  A G Awad; L N Voruganti; R J Heslegrave
Journal:  Pharmacoeconomics       Date:  1997-01       Impact factor: 4.981

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.